The effects of prednisolone treatment on bone turnover in rats were studied by biochemical markers. Female Wistar rats were randomized into three groups: (1) control; (2) prednisolone 25 mg/kg body weight (BW) (lower dose), twice a week subcutaneously; and (3) prednisolone 50 mg/kg BW (higher dose). Serum calcium, phosphorus, alkaline phosphatase (Alp), and urinary pyridinoline (Pyr) and deoxypyridinoline (Dpyr) were measured once a week for 4 weeks. Bone mineral density (BMD) of excised femur, tibia, and lumbar vertebrae were measured by dual energy X-ray absorptiometry (DXA). Dry and ash weights of excised femur were measured by conventional methods, and the content of pyridinium cross-links in tibias was measured. Higher prednisolone treatment produced a significant increase of urinary Pyr and Dpyr at weeks 3 and 4. Although serum osteocalcin was not found to be reduced in prednisolone treatment except at week 4 in the higher prednisolone treatment group, BMD and dry and ash weights of excised bones was reduced by prednisolone administration. Further, the content of Pyr and Dpyr in bone was reduced by prednisolone administration. Our findings confirm that prednisolone induced osteoporosis in rats, mainly because of the increase of bone resorption activity.
Introduction
The antiinflammatory and immunosuppressive properties of glucocorticoids have prompted their extensive use although the side effects of these potent drugs are dramatic. The patient receiving large doses of glucocorticoids is a clinically distinctive one: centripetal obesity, proximal muscle weakness, hyperglycemia, and, freOffprint requests to: M. Takahashi Received: July 18, 1997 / Accepted: Feb. 25, 1998 quently, vertebral fracture. Bone loss with resulting fractures is the most incapacitating outcome of steroid therapy. Available data suggest that the incidence of fractures is 30%-50% [1, 2] . Steroid osteoporosis is induced by the unbalancing of bone formation and bone resorption. More bone loss must be more rapid in the early weeks of glucocorticoid therapy with subsequent slowing to be deemed a side effect. One short longitudinal study suggests that there is rapid early bone loss followed by plateauing after approximately 6 months [3] . As most patients do not develop osteoporosis at the beginning of glucocorticoid therapy, it is important to identify persons at risk of osteoporosis by closer followup and by taking preventive measures. Measurement of urine calcium concentration and bone mineral density is helpful in assessing calcium balance and susceptibility to secondary hyperparathyroidism [4, 5] .
As these biochemical phenomena develop as the result of steroid-induced osteoporosis before changes are visible on the roentgenogram, estimation of bone metabolism from the beginning of glucocorticoid therapy is important. Chronic glucocorticoid excess is associated with the development of osteoporosis in human subjects. There is histomorphometric evidence of increased bone resorption and decreased bone formation in glucocorticoid-induced osteoporosis [6] [7] [8] . Calcium kinetic studies also suggest that bone resorption is increased [9, 10] . One of the reasons for this bone resorption may be explained by secondary hyperparathyroidism [6] . However, the mechanism of glucocorticoid-induced osteoporosis is not clear. Organ culture studies have demonstrated that effects on bone formation are consistent with those seen in vivo [11] , but studies of effects on bone resorption in vivo have yielded confusing results.
Measurement of bone resorption rates in animals in vivo was estimated by the loss of [ 3 H]tetracycline from bone [12, 13] , or urinary hydroxyproline excretion [14] . More recently, 3-hydroxypyridinium cross-links, which are degradation products of collagen, have been proposed as urinary markers for bone resorption. Of these, pyridinoline (Pyr) is found predominantly in bone but also in cartilage and other tissue, whereas deoxypyridinoline (Dpyr) appears to be specific to bone and dentin. Unlike hydroxyproline, changes in dietary Pyr and Dpyr do not affect those urinary concentrations [15] . Urinary pyridinium cross-links are correlated with radioisotopic measurements of bone resorption [16] , and the value of these assays as measures of bone resorption in humans has been demonstrated [17] [18] [19] . However, the use of these assays in animals has received less attention.
On the other hand, serum osteocalcin has been commonly employed clinically as a bone formation marker and used to assess the effects of experimental agents on bone metabolism in several animal models [20, 21] . Furthermore, dual energy X-ray absorptiometry (DXA) has been proved to be a precise and reliable method for measuring bone mineral density (BMD) and bone mineral content (BMC) in rats both in vivo [22] and in vitro [23] .
This study was undertaken to examine the effects of glucocorticoids on bone metabolism by measuring urinary Pyr, Dpyr, and serum osteocalcin in rats.
Materials and methods

Animals
Thirty female Wistar rats, aged 5 weeks, were used. All rats were housed in a room maintained at 23° Ϯ 2°C, with a 12-h light : dark cycle, and were fed a regular diet (Funabashi Nojyo MM-3, Chiba, Japan) containing Ca 1.6%, P 1.2%, and vitamin D 3 2.0 IU/g, and tap water ad libitum. The rats were divided randomly into three groups, and each rat was administered glucocorticoids twice a week by intramuscular injection for 4 weeks, according to the following protocol: group A (n ϭ 10), normal saline (100 µl/100 g body weight, BW); group B (n ϭ 10), prednisolone sodium succinate (25 mg/kg BW); and group C (n ϭ 10), prednisolone sodium succinate (50 mg/kg BW). Prednisolone sodium succinate was purchased from Shionogi (Osaka, Japan). Urine was collected every 24 h from each rat in its individual metabolic cage once a week and stored at Ϫ30°C until analyzed. Blood was taken by cutting the tail once a week under ether anesthesia, and the serum was stored at Ϫ70°C until assayed. One week after the final injection, all rats were killed by cardiac puncture under ether anesthesia. Tibia, femur, and lumbar vertebrae were removed and dissected from the adhering connective tissue and muscle. The vertebral body, left femur, and left tibia were stored in 70% ethanol until prepared for BMD analyzing using DXA. Right femurs were stored in 70% ethanol for analysis of bone volume, dry weight, and ash weight. Right tibias were stored at Ϫ30°C for analysis of bone Pyr, Dpyr, and hydroxyproline.
Serum markers
Serum calcium, phosphorus, and alkaline phosphatase (Alp) were measured according to standard laboratory procedures. Serum osteocalcin was measured with a modified sandwich enzyme immunoassay using the monoclonal antibody against intact rat osteocalcin [24] .
Urinary pyridinoline and deoxypyridinoline
Urinary Pyr and Dpyr were measured as previously described [25] . Briefly, each urine sample (2 ml) was hydrolyzed with an equal volume of 12 N HCl at 110°C for 20 h. The hydrolysate (0.25 ml) was mixed with 15 ml of distilled water and applied to an SP-Sephadex C25 column (0.8 ϫ 1.0 cm). After washing with 20 ml of 0.15 N HCl, Pyr and Dpyr were eluted with 5 ml of 1.0 N HCl. After evaporation, the residue was dissolved in 200 µl of a 1% heptafluorobutyric acid (HFBA) solution. The solution was stored at Ϫ30°C before high performance liquid chromatography (HPLC) analysis. Fluorescence at 390 nm was measured on excitation at 297 nm. The values of urinary Pyr and Dpyr in urine samples were expressed per millimole (mmol) of urinary creatinine. Urinary creatinine content was determined enzymatically with an aliquot of each sample before hydrolysis using a clinical chemistry analyzer (CL-20; Shimadzu, Kyoto, Japan). Using our protocol, the recoveries of standard Pyr and Dpyr were 75.4% Ϯ 2.3% for Pyr and 73.1% Ϯ 2.9% for Dpyr. The coefficients of variation of Pyr and Dpyr for several measurements, performed at different weeks, on the same urine sample were 8.3% and 9.5%, respectively.
Bone Pyr, Dpyr, and hydroxyproline
For cross-link analysis of skeletal tissue, the tissues of the tibia were decalcified with several changes of 0.5 M EDTA (pH ϭ 7.2) at 4°C for 2 weeks. After decalcification, each sample was hydrolyzed and the hydrolysate (0.25 ml) applied for the measurement of Pyr and Dpyr of bone with the same methods of urinary Pyr and Dpyr described here. The content of Pyr and Dpyr in bone was expressed per collagen molecule (mmol/mol) using values of hydroxyproline measured in aliquots of the hydrolysate by Kivirikko methods [26] .
Dry and ash weight
The volume of the femurs was measured by the Archimedes principle. The right femurs were dried at 120°C for 12 h and ashed in a muffled furnance at 800°C for 12 h. Dry and ash weight were measured with a microbalance.
Bone mineral measurements
BMD of excised femurs, tibias, and lumbar vertebrae were measured by dual energy X-ray absorptiometry (DXA) using a specifically designed software version for small animals (DPX, Small Animal Appendicular Software version 1.0; Lunar, Madison, WI, USA). The collimation (size of X-ray beam at the source) used was 0.84 mm. The size of each sample point during the scan was 0.15 ϫ 0.3 mm (hi resolution mode). After excised bone was placed on the 2-cm-thick lucite (tissue equivalent), scanning was started. The lumbar spine was scanned at the level of vertebrae L4-L5; the femur and tibia were scanned in their entirety.
Statistical analysis
The data were analyzed by two-way analysis of variance (ANOVA) with a Scheffe's test for multiple comparisons, using Statview II software on a Macintosh computer. Data are expressed as mean Ϯ SE unless otherwise noted. Values of P less than 0.05 were considered significant.
Results
Body weight
During the experiment, prednisolone-treated rats had slightly lower body weights than control rats. In group C, body weight was significantly lower at 1 week than in group A (Fig. 1) .
Serum markers
Prednisolone administration produced a significant transient decrease of serum calcium (Ca) at week 1 in group C, and at week 2 more significantly in group B than group A. At other weeks, serum Ca was not different between groups (Fig. 2) . Serum phosphorus (P) did not significantly change during prednisolone administration (Fig. 3) . Prednisolone caused a transient increase in serum Alp at week 3, especially in group C. At the same time, prednisolone did not cause a difference in serum Alp between groups at other weeks (Fig. 4) . Serum osteocalcin did not change significantly as a result of prednisolone administration from week 1 to week 3. At week 4 in group C, prednisolone lowered serum osteocalcin more significantly than in group A (Fig. 5) . 
Urinary pyridinoline and deoxypyridinoline
At week 1, urinary Pyr was lower in groups B and C than in group A and subsequently increased. At weeks 3, 4, and 5 in group C, Pyr increased more significantly than in group A (Fig. 6 ). Urinary Dpyr also decreased at week 1 in group C, followed by significant increases at weeks 3 and 4. In group B, urinary Dpyr was changed similarly to group C with a transient decrease (Fig. 7) . 
Dry and ash weight of bone
Bone volume and length of right femurs were not influenced by prednisolone administration (Table 1) . Dry weight of femurs tended to decrease by prednisolone administration, but not significantly. Ash weight of femurs in group C decreased more significantly than in group A (Fig. 8) . 
Bone mineral density
Prednisolone treatment tended to decrease BMD of the lumbar spine and the tibia, but not significantly in groups B and C. BMD of the femur decreased more significantly in group C than in group A (Fig. 9) .
Bone Pyr and Dpyr
Bone Pyr and Dpyr in group C were significantly lower than those in group A (Fig. 10) . 
Discussion
The results of the present study confirmed earlier findings that administration of prednisolone leads to a decrease in bone mass. A decrease of ash weight and bone mineral density apparently occurs during prednisolone treatment, while the bone volume of the femur was not influenced (Table 1 ; Fig. 8 ). Our results showed that 50 mg/kg prednisolone administration is probably optimal for producing bone loss in rats. However, such a high dose may result in catabolic changes and electrolytic disturbances. A glucocorticoid-induced bone loss model has been reported for rats [14, 27] when they were given a low-Ca diet. However, this may be in part the result of circulating levels of 1,25(OH) 2 D 3 . In contrast, it is difficult to demonstrate glucocorticoid-induced osteoporosis in rats unless their calcium intake is restricted [28] , in marked contrast to the situation in humans. Glucocorticoid-induced rats [29] and dogs [30] do not usually show the increase in osteoclast numbers that has repeatedly been observed in humans, although this may be partly accounted for by the higher steroid doses given to animals [31] . Further, Shepard et al. [32] found that glucocorticoids did not induce osteopenia in rats when fed commercial diets that are normal in calcium and phosphorus content. On the other hand, high doses of prednisolone induced osteoporosis in rats on regular diets [33, 34] . Thus, under a regular diet, a higher dose of prednisolone is necessary to induce glucocorticoid osteoporosis.
In human beings, there is histomorphometric evidence of increased bone resorption and decreased bone formation [35, 36] . The decreased bone formation is probably the result of a direct inhibitory effect of glucocorticoids on bone cells. The increased bone resorption appears to be caused, at least in part, by increased parathyroid hormone activity [6, 37, 38] . However, in experimental models, glucocorticoids suppressed bone resorption in in vitro studies [39, 27, 40] . The effects of glucocorticoids on bone was contradictory. There are several studies about the changes of biochemical markers under glucocorticoid treatment. Urinary hydroxyproline, a marker of bone resorption, increased under glucocorticoid treatment [41] [42] [43] , and serum osteocalcin, a marker of bone formation, decreased under glucocorticoid treatment [44] [45] [46] .
The present study was designed to evaluate the effect of glucocorticoids on bone metabolism in rats by using biochemical markers. Dpyr declined with age in the control group. This result is consistent with a progressive decline in bone turnover rates with age [47] . Both Pyr and Dpyr decreased transitionally, followed by an increase in glucocorticoid administration groups. Thus, bone resorption activity was suppressed at an earlier stage and later stimulated as a result of a high dose of prednisolone. In this study, we suggest that glucocorticoids produced a transient suppression of resorption activity followed by stimulation of bone resorption resulting from secondary hyperparathyroidism. We did not, however, measure parathyroid hormones.
Serum Alp demonstrated a transitional increase at 3 weeks in the prednisolone treatment groups, but no remarkable changes were found compared with the control group at any other period. Serum Alp, and especially bone-specific alkaline phosphatase, increases in humans from infancy to adolescence [48] . We suggest that these experimental rats were equivalent to such a transitional stage in maturity.
Previous studies have demonstrated that glucocorticoids have a biphasic effect in organ culture systems. Physiological concentrations of glucocorticoids appear to enhance the function of differentiated osteoblasts [49, 50] , although prolonged exposure and supraphysiological concentration inhibit synthetic processes. A transitional increase of serum Alp in this study may reveal a stimulating phase of prednisolone.
Serum osteocalcin levels in group C at week 4 were suppressed, although at other periods no remarkable changes were found. Thus, in this study prednisolone did not demonstrate a distinct inhibitory effect on bone formation. This observation, which is contrary to reports that glucocorticoids suppressed bone formation [39, [44] [45] [46] , may be explained by the fact that serum osteocalcin has a circadian rhythm [51] . The half-life of osteocalcin is short, which leads difficulties in evaluating the suppressive effect of prednisolone. Furthermore, this study was done with rats on regular diets. Such rats are resistant to the glucocorticoid effect [32, 52] , especially in bone formation. Therefore, in this study, prednisolone did not demonstrate an inhibitory effect on bone formation by biochemical markers. However, the amount of the cross-links of collagen (Pyr, Dpyr) of bone were decreased by prednisolone administration (Fig. 10) . This phenomenon indicates that bone formation was supressed by prednisolone.
In conclusion, bone resorption was increased and bone formation was suppressed in these rats with prednisolone-induced osteopenia.
